Procaterol

Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes^[1]. In Vitro: Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) directly inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism^[3].
Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) Dose-dependent inhibition of RANTES release in response to IL-1b and TNF-a in BEAS-2B cell monolayers, and enhancement of GM-CSF mRNA expression in response to IL-1b^[3].
Procaterol (0.1 μM, 72 h, Human tracheal surface epithelial cells) reduce rhinovirus titers and RNA, cytokine concentrations, susceptibility to rhinovirus infection, and the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for type 14 rhinovirus, and the number of acidic endosomes in the cells from which rhinovirus RNA enters into the cytoplasm^[4].
Procaterol (10 nM, one time, Lung epithelial cells) increased ciliary bend amplitude (CBA) and ciliary beating frequency (CBF) in a dose dependent manner via cAMP^[5]. In Vivo: Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) has no significant changes in weight or body weight gain in rat gastrocnemius muscle^[1].
Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) significantly increases weight of the levator ani muscle with anabolic effects^[1].
Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) increases ventral prostate weight is associated with drug stimulation of b2 adrenergic receptors in tissues^[1].
Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) different dose between bronchodilator and anabolic effects >30-fold, <100-fold^[1].
Procaterol (0.1, 1, 10 mg/kg, orally, before ovalbumin (HY-W250978) (OVA) inhalation) inhaler does not enhance airway hyperresponsiveness, airway wall inflammation, or airway wall thickening, and decreases eosinophil number^[2].